Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
The Ministry of Health, Labor and Welfare (MHLW) announced its new pharmaceutical industry vision on September 13, highlighting the importance of predictability that would enable companies to expect appropriate rewards for their investments in Japan. The pharma industry vision 2021,…
To read the full story
Related Article
- Working Group Launched under Pharma Industry Vision Meets for 1st Time
March 31, 2022
- JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
- Japan Eyes Legal System to Ensure Generic Supplies in New Industry Vision, Key Official Says It’s Difficult with Companies’ Own Efforts Alone
September 15, 2021
- Generic Trade Group Sets Out 4 Pledges on Quality, Stable Supply
September 15, 2021
- FPMAJ Vows to Work towards Achieving New Pharma Industry Vision
September 15, 2021
- PhRMA Hails Japan's New Pharma Industry Vision
September 14, 2021
- Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
- New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
August 23, 2021
- Public-Private Dialogue for New Pharma Vision Set for Aug. 24
August 18, 2021
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…